OREANDA-NEWS. On September 4, the Russian Direct Investment Fund (RDIF), the Russian National Wealth Fund, and the Gamaleya Research Institute of Epidemiology and Microbiology published an article in the medical journal Lancet on the results of the first and second phases of clinical trials of the coronavirus vaccine Sputnik V. The publication summarizes the results of trials in humans and mentions previously unpublished data on preclinical studies in animals: primates, mice and hamsters.

As stated in the report of the RDIF, the scientific data presented in the article prove “the high safety and effectiveness of the Russian vaccine,” and the characteristics of the drug distinguish it favourably from other vaccines. In particular, the developers state that according to the results of trials, no serious adverse effects were detected, while the level of such effects for other vaccines ranges from 1 to 25 %.

According to RDIF head Kirill Dmitriev, the publication in the Lancet demonstrates the recognition of Russian scientists by the world scientific community, as well as Russia’s readiness for dialogue.